A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent (Q6643860)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent |
scientific article; zbMATH DE number 7949817
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent |
scientific article; zbMATH DE number 7949817 |
Statements
A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent (English)
0 references
27 November 2024
0 references
drug combination
0 references
immunotherapy
0 references
Bayesian adaptive design
0 references
dose-finding
0 references
risk-benefit tradeoff
0 references
